September 16, 2025- Thermo Fisher Scientific Inc. unveiled the Gibco™ Efficient-Pro™ Medium (+) Insulin, a next-generation medium designed to increase titers to maximize productivity and elevate the performance of insulin-dependent CHO cell lines. Efficient-Pro Medium (+) Insulin is the latest addition to Thermo Fisher’s existing Efficient-Pro medium and feed system, designed to provide optimized growth and productivity for insulin-dependent CHO cell lines, with streamlined workflow and handling.
Designed for Biopharma Manufacturers, Biotechnology Companies, and CDMOs Focused on CHO-Based Therapeutics:
Efficient-Pro Medium (+) Insulin offers improved protein yield and optimized productivity for insulin-dependent CHO cell lines commonly used in monoclonal antibody and biosimilar production, while also simplifying the preparation process and logistics. Biopharma manufacturers, biotechnology companies, and contract development and manufacturing organizations (CDMOs) can benefit from the following:
- Industry leaders want higher protein titers – our solution offers up to 61% higher protein titers compared to other alternatives;
- High viable cell densities and robust growth, all without compromising product quality;
- Compatibility with a broad range of insulin-dependent CHO cell lines and increased flexibility through a variety of formats and packaging configurations;
- Dry format compatibility via Thermo Fisher’s Gibco™ Advanced Granulation Technology™ (AGT™) dry media, enabling ease of use, rapid reconstitution and scalability and
- Animal origin–free (AOF) formulation that reduces process variability and eases regulatory complexity, helping customers achieve dependable results with greater peace of mind.
For protein therapeutic developers (e.g., mAb, bispecific, Fc-fusion proteins, etc.), Efficient-Pro Medium (+) Insulin simplifies process development by providing consistent, high-performance growth and production conditions with reduced variability.